Itoh K, Sawamura Y, Hosokawa M, Kobayashi H
Department of Nuclear Medicine, School of Medicine, Hokkaido University, Japan.
Radiat Med. 1988 Nov-Dec;6(6):276-81.
This study was undertaken to assess the in vivo distribution and migration of lymphokine-activated killer (LAK) cells to the target malignant foci in four patients with advanced malignant brain tumor. All four patients had failed to respond to prior adoptive immunotherapy. After the intravenous administration of radiolabeled LAK cells, most of the radiolabeled cells were distributed in the liver and spleen, with lesser radioactivity in the lung and bone marrow. Scintigraphy revealed the target malignant foci in all four patients to be areas of increased radioactivity. The number of radiolabeled LAK cells that accumulated in the intracranial malignant lesions, however, seemed to be insufficient to mediate regression of the solid tumor mass by direct cell-to-cell interaction. We conclude that the failure of adoptive immunotherapy could be accounted for by the poor migration of infused LAK cells to the target malignant foci. We also conclude that radionuclide study with radiolabeled lymphokine-activated culture cells against tumors is likely to be helpful as a means to investigate effective possibilities for subsequent adoptive immunotherapy.
本研究旨在评估4例晚期恶性脑肿瘤患者体内淋巴因子激活的杀伤（LAK）细胞向靶恶性病灶的分布及迁移情况。所有4例患者既往接受过过继性免疫治疗但均无效。静脉注射放射性标记的LAK细胞后，大部分放射性标记细胞分布于肝脏和脾脏，肺和骨髓中的放射性较低。闪烁扫描显示所有4例患者的靶恶性病灶均为放射性增强区域。然而，积聚在颅内恶性病变中的放射性标记LAK细胞数量似乎不足以通过直接的细胞间相互作用介导实体瘤块的消退。我们得出结论，过继性免疫治疗失败可能是由于注入的LAK细胞向靶恶性病灶的迁移不佳所致。我们还得出结论，用放射性标记的针对肿瘤的淋巴因子激活培养细胞进行放射性核素研究，可能有助于作为一种手段来研究后续过继性免疫治疗的有效可能性。
